Financial Performance - For the fiscal year ended June 30, 2024, the company reported a net loss of approximately $8.5 million and an accumulated deficit of approximately $159.9 million[82][83]. - Research and development expenses for the years ended June 30, 2024, and 2023 were approximately $2.7 million and $9.3 million, respectively[77]. - As of June 30, 2024, the company had cash and cash equivalents of approximately $4.9 million, which is expected to fund operations for less than one year[85]. - The company has expressed substantial doubt about its ability to continue as a going concern due to the lack of generated revenues and the need for additional funding[81][82]. Clinical Development and Studies - The REM-001 therapy demonstrated an 80% complete response rate in evaluable tumor sites treated in previous studies[9]. - The company is conducting a 15-patient open-label study for REM-001, with four patients dosed as of October 7, 2024[7]. - The proposed merger with TuHURA is expected to be completed in mid-October 2024, subject to regulatory approval[7]. - The company plans to conduct a Phase 3 clinical study in CMBC following the initial 15-patient study[12]. - The REM-001 program was re-initiated after receiving the NIH grant, with enrollment expected to be completed in Q4 2024[10]. - The company has received Fast Track Designation from the FDA for REM-001 in CMBC[11]. - REM-001 has been safely administered to over 1,100 patients in prior clinical studies, indicating a strong safety profile[15]. - In a Phase 1/2 clinical study for BCCNS, REM-001 showed a 91% overall response rate, with a 68% complete response rate[22]. - The most common treatment-related adverse event in CMBC studies was pain, with transient photosensitivity also reported[16]. - Current standard treatments for CMBC are often inadequate due to limited efficacy and side effects, indicating a significant unmet medical need[24]. Regulatory and Compliance - The company is dependent on regulatory approvals for commercialization, which involves rigorous testing and compliance with various regulations[44][46]. - The FDA offers expedited approval mechanisms for selected drugs, including fast track and breakthrough designations, but it is currently undetermined if these will apply to the company's drug candidates[53]. - Regulatory approval processes for products are lengthy and require substantial resources, with an average NDA review taking 10 months[50][51]. - The company may need to conduct post-marketing studies and comply with ongoing regulatory requirements, which could incur additional costs[160]. - The company is subject to extensive government regulations that require approval for manufacturing and marketing therapeutic products, which can be costly and time-consuming[116]. Market and Competition - The estimated market opportunity for the treatment of CMBC is approximately $500 million[19]. - The company faces significant competition in the oncology market, with major pharmaceutical and biotechnology companies actively developing similar products[66]. - Many competitors have greater financial resources and expertise in R&D, manufacturing, and obtaining marketing approvals, which could impact the company's market position[71]. - The oncology market is characterized by a large unmet medical need and competitive dynamics, with numerous therapies currently available for treating conditions like CMBC[69]. - If competitors obtain FDA approval before the company, they may establish a strong market position, reducing the company's commercial opportunity[164]. Merger and Corporate Structure - The merger agreement with TuHURA is expected to result in stockholders owning approximately 2.85% of the combined company on a pro forma fully diluted basis, increasing to 5.45% including CVR shares[73]. - TuHURA stockholders are expected to own approximately 97.15% of the combined company on a pro forma fully diluted basis[74]. - A reverse stock split was approved by stockholders to be executed prior to the consummation of the proposed merger, with a ratio between 1-for-20 and 1-for-40[89]. - The company operates with a "virtual" corporate structure, employing one full-time employee and approximately 10 independent contractors[78]. - The anticipated benefits and cost savings from the merger may not be realized, with risks including integration challenges and potential litigation[199]. Intellectual Property and Patents - The company holds two INDs for REM-001 in oncology and ophthalmology, and one NDA for treating age-related macular degeneration[43]. - The patent applications for REM-001 include methods for production and treatment of cutaneous metastatic cancers, with some applications pending in various countries[41][42]. - The company does not hold any patents covering its laser light source or light delivery device for REM-001, which may allow competitors to offer similar products[110]. - The company is dependent on obtaining certain patents and protecting proprietary rights, which are crucial for its success in the market[101]. Risks and Uncertainties - Failure to successfully complete clinical studies or obtain regulatory approvals could adversely affect the company's financial condition and operational results[72]. - The company may encounter delays in obtaining coverage and reimbursement for newly approved drugs, which could negatively impact revenue generation[98]. - The company may experience unforeseen events during clinical studies that could delay or prevent marketing approval of product candidates[129]. - Delays in patient enrollment for clinical studies could significantly impact the development timeline and regulatory approval of product candidates, including REM-001[131]. - The company faces challenges in maintaining effective internal control over financial reporting, which could impact the accuracy and timeliness of financial results[92]. Funding and Financial Obligations - The company is obligated to pay a total of $300,000 upon the completion of a Phase 2B clinical study and $700,000 upon receipt of regulatory approval for REM-001 Therapy[37][38]. - A royalty fee of 6% of net sales will be paid to St. Cloud and Steven Rychnovsky, PhD, with St. Cloud receiving 4.8% and Rychnovsky receiving 1.2%[39]. - The company may incur a termination fee of $1,000 to TuHURA if the merger is not completed under specified circumstances[197]. - The company does not intend to pay cash dividends on common stock for the foreseeable future, with all earnings expected to be retained for future expansion[195].

Merger and Corporate Changes - Kintara Therapeutics completed a merger with TuHURA Biosciences, issuing approximately 40,441,605 shares of common stock to TuHURA stockholders based on an exchange ratio of 0.1789[74]. - Following the merger, Kintara's common stock began trading under the new symbol "HURA" on October 18, 2024, after a 1-for-35 reverse stock split[76]. - The company completed the merger with TuHURA on October 18, 2024, and changed its name to TuHURA Biosciences, Inc.[86]. - TuHURA stockholders owned approximately 97.15% of Kintara on a fully-diluted basis immediately prior to the merger[76]. - The merger agreement included provisions for contingent value rights, allowing stockholders to receive approximately 1,539,918 shares of common stock upon achieving specific clinical milestones[76]. Clinical Development and Research - The company received a $2,000 grant from the NIH to fund the REM-001 CMBC clinical study, which is expected to complete patient enrollment in Q4 2024[77]. - REM-001 therapy demonstrated a complete response in approximately 80% of evaluable tumor sites treated in previous studies for cutaneous metastatic breast cancer[78]. - Kintara received Fast Track Designation from the FDA for REM-001 in CMBC, facilitating its clinical development[80]. - The company has initiated treatment in four patients as part of the REM-001 study at Memorial Sloan Kettering Cancer Center as of November 14, 2024[79]. - The development of VAL-083 was terminated after preliminary results showed it did not perform better than current standards of care for glioblastoma[81]. Financial Performance - As of September 30, 2024, the company reported cash and cash equivalents of $3,020,000, down from $4,909,000 as of June 30, 2024[87]. - For the three months ended September 30, 2024, research and development expenses decreased to $252,000 from $1,859,000 for the same period in 2023, a reduction of 86%[88]. - General and administrative expenses increased to $1,957,000 for the three months ended September 30, 2024, compared to $1,103,000 for the same period in 2023, an increase of 77%[88]. - The net loss for the three months ended September 30, 2024, was $2,161,000, an improvement from a net loss of $2,962,000 for the same period in 2023[88]. - The company reported a negative cash flow from operating activities of $1,889,000 for the three months ended September 30, 2024, compared to a negative cash flow of $1,317,000 for the same period in 2023, a change of 43%[95]. - The accumulated deficit as of September 30, 2024, was $162,052,000, with no revenues generated to date[100]. - The company raised approximately $10,471,000 in net proceeds from the sale of common stock under the ATM Facility from October 31, 2023, to September 30, 2024[100]. - The company recorded $13,000 in dividends related to Series C Preferred Stock for the three months ended September 30, 2024, down from $173,000 for the same period in 2023[94]. Operational Strategies - The company aims to address unmet medical needs in cancer therapy, focusing on orphan cancer indications[72]. - The company is exploring various financing alternatives to fund operations and maximize shareholder value following the merger[101]. Accounting and Estimates - The company provided a detailed presentation of significant accounting policies and estimates in its Annual Report on Form 10-K for the year ended June 30, 2024, filed on October 7, 2024[103]. - For the three months ended September 30, 2024, the company issued stock options to its officers, with fair value determined using the Black-Scholes model, which includes variables such as expected volatility, interest rates, and dividend yields[104]. - The company estimates expenses related to research and development and clinical trials based on contracts with vendors and clinical research organizations, adjusting accrual estimates as necessary[105]. - There were no material adjustments to prior period estimates of accrued expenses for clinical trials for the three months ended September 30, 2024, and 2023[105]. - The company does not have any off-balance sheet arrangements[106].

Merger and Acquisition - The merger between Kintara and TuHURA resulted in TuHURA stockholders owning approximately 96.0% of the combined company post-merger[4]. - The Exchange Ratio for the merger was calculated to be 0.1789 following a 1-35 reverse share split[6]. - The merger transaction was completed on April 2, 2024, with TuHURA continuing as a wholly owned subsidiary of Kintara[16]. - The pro forma financial statements reflect the merger as if it had been consummated on January 1, 2023, with no historical operating relationship between the companies prior to the merger[5]. - The pro forma combined entity reflects a reverse share split of 1-35, impacting the number of shares outstanding[17]. - TuHURA's existing shareholders will own approximately 96.0% of the combined company post-merger, while Kintara's existing public stockholders will own about 4.0%[18]. Financial Performance - Total assets held by TuHURA and Kintara as of June 30, 2024, were $14,093 thousand and $6,202 thousand, respectively, with cash and cash equivalents of $12,311 thousand and $4,909 thousand[4]. - As of June 30, 2024, TuHURA's total current assets amounted to $23,069,000, with cash and cash equivalents at $22,043,000[9]. - Total liabilities for TuHURA as of June 30, 2024, were reported at $5,124,000, with current liabilities at $4,813,000[10]. - For the six months ended June 30, 2024, TuHURA reported total operating expenses of $12,694,000, with research and development expenses at $7,105,000[12]. - The net loss for TuHURA for the same period was $12,494,000, resulting in a net loss per share of $0.30[12]. - TuHURA's total stockholders' equity (deficit) was reported at $3,757,000 as of June 30, 2024[11]. - Total operating expenses for the pro forma combined entity amounted to $49,525,000, with research and development expenses contributing $20,753,000[14]. - The net loss for the pro forma combined entity was $49,011,000, resulting in a net loss per share of $1.17[14]. Research and Development - TuHURA plans to launch the REM-001 Study, a second-generation PDT photosensitizer agent, to test a 0.8 mg dose and optimize study design ahead of a Phase 3 trial initiation[4]. - TuHURA anticipates successful enrollment of ten CMBC patients for the REM-001 Study, with no significant value expected from Kintara's in-process research and development assets at the time of the merger[4]. - Kintara entered into a Contingent Value Rights Agreement, allowing holders to receive shares based on achieving a milestone related to the REM-001 study[20]. - Initial results from KVA12123 showed partial response and stable disease in combination cohorts, with durable stable disease in monotherapy cohorts[31]. - As of August 19, 2024, 30 out of a projected 39 patients have been enrolled in the ongoing VISTA-101 Phase 1/2 clinical trial[31]. - KVA12123 has cleared five of six monotherapy dose levels and two of four cohorts in combination with Merck's KEYTRUDA® therapy[31]. Financing and Debt - The convertible promissory notes issued by TuHURA were increased to an aggregate principal amount of $35 million, with a simple interest rate of 20% per annum[7]. - TuHURA's board approved a private offering of Convertible Debt, increasing the aggregate principal amount to $35 million, primarily for clinical development and corporate expenses[19]. - The Convertible Debt bears simple interest at a rate of 20% per annum, computed on a 365-day year[30]. - The company plans to convert Convertible Debt of $22,242,770 into 55,489,176 shares upon merger completion[34]. - The company recorded a reversal of interest expense on Convertible Debt of $1,612,610 for the six months ended June 30, 2024[34]. - The fair value of the derivative liability related to the Convertible Debt was recorded at $2,884,000[34]. Agreements and Transactions - TuHURA has entered into an Exclusivity Agreement with Kineta for the potential acquisition of the KVA12123 anti-VISTA antibody and related assets[7]. - TuHURA paid Kineta a total fee of $5,000,000 under the Exclusivity Agreement, with $2,500,000 paid at signing and another $2,500,000 due on July 15, 2024[8]. - The company has not allocated any of the $5,000,000 purchase price consideration to the royalty agreement due to uncertainties surrounding regulatory approval of KVA12123[8]. - TuHURA made nonrefundable payments of $5,000,000 for exclusive rights to acquire Kineta's patents and related assets[33]. - Estimated transaction costs related to the merger amount to $3,827,530, including a one-time special bonus of $327,030[34]. - The issuance of 4,009,623 shares in July 2024 Private Placement generated proceeds of $5,000,000, netting $4,695,990 after costs[32].

Core Viewpoint - Kintara Therapeutics, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-35, effective October 18, 2024, following its merger with TuHURA Biosciences, Inc. [1][2] Company Overview - Kintara Therapeutics is focused on developing new solid tumor cancer therapies and is headquartered in San Diego, California [7][9] - The company is dedicated to addressing unmet medical needs in cancer treatment, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer (CMBC) [7][8] Reverse Stock Split Details - The reverse stock split will reduce the number of Kintara's outstanding common shares from approximately 55.6 million to about 1.6 million [3] - The par value of Kintara's common stock will remain unchanged at $0.001 per share, and the authorized number of shares will not change [3] - The reverse stock split will apply uniformly to all stockholders, with adjustments made for any fractional shares [3] Merger with TuHURA Biosciences - Following the merger, the combined company's total outstanding common stock is expected to be approximately 42.0 million shares [4] - TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing technologies to overcome resistance to cancer immunotherapy [5] - TuHURA's lead candidate, IFx-2.0, aims to enhance the effectiveness of checkpoint inhibitors in treating advanced Merkel Cell Carcinoma [5][6]

Core Viewpoint - Kintara Therapeutics has approved a reverse stock split at a ratio of 1-for-35, which will take effect on October 17, 2024, coinciding with the merger with TuHURA Biosciences, Inc. The company will trade under the new name TuHURA Biosciences, Inc. with the symbol "HURA" [1][4]. Summary by Sections Reverse Stock Split - The reverse stock split was approved by Kintara's stockholders on October 4, 2024, with a final ratio of 1-for-35 determined by the Board [2]. - This action will reduce the number of outstanding shares from approximately 55.6 million to about 1.6 million shares, while the par value remains at $0.001 per share [3]. - The reverse stock split will not change the authorized number of shares and will uniformly affect all stockholders, with no fractional shares issued [3]. Merger with TuHURA Biosciences - Following the merger, the combined company's total outstanding common stock is expected to be approximately 42.0 million shares [4]. - TuHURA Biosciences is focused on developing novel immuno-oncology therapies, including a personalized cancer vaccine candidate, IFx-2.0, which is set to enter a Phase 3 trial [5][6]. Company Background - Kintara Therapeutics is dedicated to developing novel cancer therapies, particularly for patients with unmet medical needs, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [7][8]. - The company has a proprietary photodynamic therapy platform that has shown an 80% clinical efficacy in previous trials for its lead therapy [8].

Core Viewpoint - Kintara Therapeutics is advancing its business through a merger with TuHURA Biosciences, aiming to enhance its capabilities in developing cancer therapies while reporting improved financial results for the fiscal year 2024. Recent Corporate Developments - Kintara entered into a definitive merger agreement with TuHURA Biosciences, which is focused on immune-oncology and developing technologies to overcome resistance to cancer immunotherapy [2] - The merger is expected to be completed in mid-October 2024, following stockholder approval received on October 4, 2024 [3] Financial Results Summary - As of June 30, 2024, Kintara reported cash and cash equivalents of approximately $4.9 million, an increase from $1.5 million in the previous year [5][7] - For the three months ended June 30, 2024, Kintara reported a net loss of approximately $2.3 million, a decrease from a net loss of $3.3 million for the same period in 2023, attributed to lower research and development expenses [6] - For the fiscal year ended June 30, 2024, the total net loss was approximately $8.3 million, down from $14.6 million in the previous year [8] Selected Balance Sheet Data - Working capital increased to $3.3 million as of June 30, 2024, compared to $0.2 million in the prior year [7] - Total assets rose to $6.2 million from $4.0 million year-over-year [7] Clinical Development Update - Kintara has initiated an open-label study involving 15 patients for its REM-001 therapy in cutaneous metastatic breast cancer, with four patients dosed as of October 7, 2024 [4] - The majority of the costs for the REM-001 study will be funded by a $2.0 million grant from the National Institutes of Health [4] About Kintara - Kintara is dedicated to developing novel cancer therapies, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer, which has shown an 80% clinical efficacy in previous trials [10][11]

Core Points - Kintara Therapeutics has adjourned its Special Meeting of Stockholders due to not reaching the voting threshold for Proposals 3 and 5, which are related to increasing authorized shares and reincorporation from Nevada to Delaware [2][3] - The Special Meeting will reconvene on October 4, 2024, at 9:00 a.m. Eastern Time [1] - The record date for stockholders entitled to vote remains August 14, 2024, and previously submitted proxies will be voted at the adjourned meeting unless revoked [3] Company Overview - Kintara Therapeutics is focused on developing novel cancer therapies, particularly for patients with unmet medical needs, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [6][7] - The company utilizes a proprietary photodynamic therapy platform, which has shown an 80% clinical efficacy in complete responses for evaluable lesions in CMBC patients [7] - Kintara is headquartered in San Diego, California, and aims to address significant medical needs with reduced risk development programs [6][8] Proposed Merger - Kintara is in the process of a proposed merger with TuHURA Biosciences, which is developing immuno-oncology technologies to overcome resistance to cancer therapies [2][4] - TuHURA's lead product candidate, IFx-2.0, is designed to enhance the effectiveness of checkpoint inhibitors in treating advanced or metastatic Merkel Cell Carcinoma [4] - The merger is contingent upon stockholder approval and the completion of necessary regulatory filings with the SEC [11][12]

Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on proposals necessary for the completion of its merger with TuHURA Biosciences, emphasizing the importance of stockholder approval for the future of the company [1][2][4]. Group 1: Merger Details - The proposed merger with TuHURA requires a "FOR" vote on Proposals 3 & 5 from a majority of Kintara's voting power as of August 14, 2024 [1][2]. - Proposal 3 seeks approval to amend Kintara's Articles of Incorporation to increase the number of authorized shares [4]. - Proposal 5 involves the reincorporation of Kintara from Nevada to Delaware, along with a plan of conversion [5]. Group 2: Voting Information - Stockholders must cast their votes by 11:59 p.m. ET on September 19, 2024, to ensure their votes count [1][6]. - Voting can be done via phone or internet, with specific instructions provided for different platforms [5][6]. Group 3: Company Background - Kintara Therapeutics focuses on developing new therapies for solid tumors, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [9][10]. - The company has a proprietary photodynamic therapy platform that has shown an 80% clinical efficacy in previous trials [10]. Group 4: TuHURA Biosciences Overview - TuHURA is an immuno-oncology company in Phase 3 development, working on technologies to overcome resistance to cancer immunotherapy [7]. - Its lead product candidate, IFx-2.0, aims to enhance the effectiveness of existing treatments like Keytruda® for advanced Merkel Cell Carcinoma [7][8].

Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on the proposed merger with TuHURA Biosciences, which aims to create a combined company focused on advancing a diversified late-stage oncology pipeline [1][3]. Company Overview - Kintara Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to developing novel cancer therapies for patients with unmet medical needs [10][12]. - The company's lead program is REM-001 Therapy, which targets cutaneous metastatic breast cancer (CMBC) and has shown an 80% clinical efficacy rate in previous trials [11]. Merger Details - The merger agreement is an all-stock transaction, with pre-merger Kintara equityholders expected to own approximately 2.85% of the combined company, while pre-merger TuHURA equityholders are expected to own about 97.15% [3]. - The combined entity will operate under the name "TuHURA Biosciences, Inc." and will trade on The Nasdaq Capital Market under the ticker "HURA" [3]. - The transaction is anticipated to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval from both companies [3]. TuHURA Biosciences Overview - TuHURA Biosciences is an immuno-oncology company in the Phase 3 registration stage, developing technologies to overcome resistance to cancer immunotherapy [8]. - The lead candidate, IFx-2.0, is designed to be used alongside Keytruda® for treating advanced or metastatic Merkel Cell Carcinoma [8]. Voting Information - Stockholders must vote by 11:59 p.m. Eastern Time on September 19, 2024, for their votes to count, and those eligible to vote include stockholders as of August 14, 2024 [5][6]. - Voting can be conducted via phone or internet, with specific instructions provided for different platforms [6][7].

Core Viewpoint - TuHURA Biosciences has entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody, which is in development as an immunotherapy for cancer treatment [1][8]. Company Overview - TuHURA Biosciences is a Phase 3 registration-stage immune-oncology company focused on developing technologies to overcome resistance to cancer immunotherapy [1][9]. - Kintara Therapeutics is a biopharmaceutical company dedicated to developing new therapies for solid tumors, with a focus on unmet medical needs [3][22]. Product Development - KVA12123 is a VISTA blocking immunotherapy currently completing clinical trials as both a monotherapy and in combination with Merck's KEYTRUDA® for patients with advanced solid tumors [2][8]. - KVA12123 has shown strong tumor growth inhibition in preclinical models without inducing cytokine release syndrome (CRS) in clinical trials, differentiating it from other therapies targeting VISTA [2][19]. Financial Terms - Under the Agreement, TuHURA will pay Kineta a total of $5 million, with an initial payment of $2.5 million at signing and an additional $2.5 million due by July 15, 2024 [8]. - TuHURA also raised $5 million through a private offering to an existing shareholder to support its operations [8][25]. Strategic Goals - The combined company from the merger of TuHURA and Kintara will focus on advancing personalized cancer vaccines and bi-functional antibody-drug conjugates (ADCs) to address major challenges in current cancer immunotherapy [26][27]. - The merger is expected to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval [26].